{"id":"folfiri-3","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Neutropenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The combination of these drugs works synergistically to inhibit thymidylate synthase, topoisomerase I, and other enzymes essential for DNA replication and cell division. This leads to DNA damage and ultimately cell death in rapidly dividing cancer cells.","oneSentence":"FOLFIRI is a chemotherapy regimen that combines 5-fluorouracil, leucovorin, irinotecan, and folinic acid to target rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:32:32.522Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"}]},"trialDetails":[{"nctId":"NCT07498725","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"LARKSPUR BIOSCIENCES, INC.","startDate":"2026-05","conditions":"Neoplasms","enrollment":120},{"nctId":"NCT07221357","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-12-31","conditions":"Untreated, Unresectable, or Metastatic Colorectal Cancer","enrollment":990},{"nctId":"NCT06252649","phase":"PHASE3","title":"Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-07-17","conditions":"Metastatic Colorectal Cancer","enrollment":450},{"nctId":"NCT02758951","phase":"PHASE2, PHASE3","title":"Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Koen Rovers","startDate":"2017-06-01","conditions":"Colorectal Neoplasm, Colorectal Cancer, Colorectal Neoplasms Malignant","enrollment":358},{"nctId":"NCT07486492","phase":"EARLY_PHASE1","title":"Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2026-03-31","conditions":"Colorectal Cancer Metastatic, Fecal Microbiota Transplantation","enrollment":10},{"nctId":"NCT06662786","phase":"PHASE3","title":"A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-10-18","conditions":"Colorectal Neoplasms","enrollment":1000},{"nctId":"NCT03715933","phase":"PHASE1","title":"Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas","status":"RECRUITING","sponsor":"Inhibrx Biosciences, Inc","startDate":"2018-10-08","conditions":"Ewing Sarcoma","enrollment":321},{"nctId":"NCT05239741","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-04-02","conditions":"Colorectal Neoplasms","enrollment":100},{"nctId":"NCT02890355","phase":"PHASE2","title":"FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-09-01","conditions":"Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7","enrollment":123},{"nctId":"NCT04929223","phase":"PHASE1","title":"A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-22","conditions":"Metastatic Colorectal Cancer","enrollment":542},{"nctId":"NCT06047379","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":"Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult","enrollment":134},{"nctId":"NCT07441369","phase":"PHASE2","title":"Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Fudan University","startDate":"2026-03-01","conditions":"Liver Metastases From Colorectal Cancer (mCRC)","enrollment":16},{"nctId":"NCT05083481","phase":"PHASE1, PHASE2","title":"A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-10-19","conditions":"Advanced Solid Tumors","enrollment":366},{"nctId":"NCT07193862","phase":"EARLY_PHASE1","title":"Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis","status":"RECRUITING","sponsor":"Northwell Health","startDate":"2025-12-10","conditions":"Colorectal Cancer Metastatic","enrollment":10},{"nctId":"NCT05286814","phase":"PHASE2","title":"PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-10-24","conditions":"Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer","enrollment":70},{"nctId":"NCT07184047","phase":"","title":"Frailty Scales for Predicting Chemotherapy Toxicity in Older Adults With Gastrointestinal Cancers","status":"COMPLETED","sponsor":"Ankara Etlik City Hospital","startDate":"2024-01-15","conditions":"Gastrointestinal Cancers, Frailty, Sarcopenia in Elderly","enrollment":72},{"nctId":"NCT04485013","phase":"PHASE1","title":"TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers","status":"RECRUITING","sponsor":"Tizona Therapeutics, Inc","startDate":"2020-07-14","conditions":"Cancer","enrollment":240},{"nctId":"NCT06750094","phase":"PHASE3","title":"A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-12-12","conditions":"Colorectal Neoplasms","enrollment":700},{"nctId":"NCT06728072","phase":"PHASE2","title":"Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer","status":"RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2025-03-07","conditions":"Colorectal Cancer, CRC","enrollment":97},{"nctId":"NCT00208260","phase":"PHASE2, PHASE3","title":"Intensified Chemotherapy in CRC After Resection of Liver Metastases","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2004-04","conditions":"Colorectal Cancer, Liver Metastases, Chemotherapy","enrollment":124},{"nctId":"NCT07389265","phase":"PHASE3","title":"Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2025-10-01","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":480},{"nctId":"NCT06771622","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"FBD Biologics Limited","startDate":"2025-03-13","conditions":"Solid Cancer","enrollment":500},{"nctId":"NCT07381309","phase":"PHASE2","title":"Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM","status":"NOT_YET_RECRUITING","sponsor":"Jun Huang","startDate":"2026-02-01","conditions":"CRC, Liver Metastasis Colon Cancer","enrollment":114},{"nctId":"NCT07265674","phase":"PHASE3","title":"A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer","status":"RECRUITING","sponsor":"J-Pharma Co., Ltd.","startDate":"2026-01","conditions":"Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC)","enrollment":480},{"nctId":"NCT07042685","phase":"PHASE2","title":"Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-02","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":50},{"nctId":"NCT05332002","phase":"PHASE2","title":"sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2022-07-13","conditions":"Gastro-Intestinal Cancer","enrollment":38},{"nctId":"NCT06332079","phase":"PHASE2","title":"Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients","status":"TERMINATED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2024-03-13","conditions":"Colorectal Cancer Metastatic","enrollment":4},{"nctId":"NCT03803553","phase":"PHASE3","title":"Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-04-16","conditions":"Metastatic Colon Cancer, Stage III Colon Cancer","enrollment":400},{"nctId":"NCT05836324","phase":"PHASE1","title":"A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2023-07-24","conditions":"Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":408},{"nctId":"NCT04329494","phase":"PHASE1","title":"PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-08-21","conditions":"Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8","enrollment":49},{"nctId":"NCT07271355","phase":"PHASE3","title":"Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-07-01","conditions":"Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum","enrollment":129},{"nctId":"NCT06333314","phase":"PHASE2","title":"Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-07-23","conditions":"Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma","enrollment":120},{"nctId":"NCT07158164","phase":"PHASE4","title":"DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2025-08-27","conditions":"Colorectal Neoplasms, Breast Neoplasms, Head and Neck Neoplasms","enrollment":100},{"nctId":"NCT04205968","phase":"PHASE2","title":"Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2020-06-01","conditions":"Metastatic Small Intestinal Adenocarcinoma, Stage III Small Intestinal Adenocarcinoma AJCC v8, Stage IIIA Small Intestinal Adenocarcinoma AJCC v8","enrollment":94},{"nctId":"NCT07150403","phase":"PHASE2","title":"Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2025-12-31","conditions":"Metastatic Colorectal Carcinoma (mCRC)","enrollment":74},{"nctId":"NCT06490536","phase":"PHASE3","title":"The Sagittarius Trial","status":"RECRUITING","sponsor":"IFOM ETS - The AIRC Institute of Molecular Oncology","startDate":"2024-10-22","conditions":"Colon Cancer Stage II, Colon Cancer Stage III","enrollment":700},{"nctId":"NCT06867822","phase":"PHASE1","title":"Trial of ProAgio in Advanced/Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-07-17","conditions":"Advanced Colorectal Cancer, Metastatic Colorectal Cancer","enrollment":27},{"nctId":"NCT03872947","phase":"PHASE1","title":"A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Toray Industries, Inc","startDate":"2019-04-26","conditions":"Solid Tumor, Colorectal Cancer, Cholangiocarcinoma","enrollment":138},{"nctId":"NCT04348045","phase":"PHASE2","title":"Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status.","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2020-12-07","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":307},{"nctId":"NCT06055179","phase":"NA","title":"XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial)","status":"RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2024-03-08","conditions":"Xiao Chai Hu Tang, Irinotecan-induced Diarrhea","enrollment":98},{"nctId":"NCT05330429","phase":"PHASE2","title":"Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2022-07-08","conditions":"Metastatic Colorectal Cancer","enrollment":77},{"nctId":"NCT02419495","phase":"PHASE1","title":"Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-06-26","conditions":"Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":221},{"nctId":"NCT02720068","phase":"PHASE1","title":"Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-05-02","conditions":"Neoplasms","enrollment":481},{"nctId":"NCT05312398","phase":"PHASE2","title":"CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2021-07-15","conditions":"Metastatic Colorectal Adenocarcinoma","enrollment":219},{"nctId":"NCT06794086","phase":"PHASE3","title":"SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases","status":"RECRUITING","sponsor":"Jun Huang","startDate":"2025-04-10","conditions":"Colorectal Cancer, Liver Metastases","enrollment":24},{"nctId":"NCT02934529","phase":"PHASE3","title":"Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2015-03","conditions":"Metastatic Colorectal Cancer","enrollment":673},{"nctId":"NCT03597581","phase":"PHASE1","title":"A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"Inspirna, Inc.","startDate":"2018-06-05","conditions":"Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer","enrollment":89},{"nctId":"NCT04256707","phase":"PHASE1, PHASE2","title":"Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment","status":"COMPLETED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-01-14","conditions":"Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC), Other Solid Tumors","enrollment":126},{"nctId":"NCT06857773","phase":"PHASE3","title":"Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic Therapy","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2024-11-21","conditions":"Colorectal Neoplasms, Floxuridine, Liver Metastases","enrollment":306},{"nctId":"NCT06843954","phase":"PHASE4","title":"Impact of Vascular Endothelial Growth Factor Gene Polymorphisms on Bevacizumab Efficacy in a Sample of Iraqi Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Mohammed Mahmood Mohammed","startDate":"2022-09-01","conditions":"Colo-rectal Cancer","enrollment":157},{"nctId":"NCT06841159","phase":"PHASE2","title":"Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-03-01","conditions":"Microsatellite Stable Metastatic Colorectal Cancer","enrollment":116},{"nctId":"NCT05087992","phase":"PHASE1","title":"A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-11-24","conditions":"Gastrointestinal Cancer, Metastatic","enrollment":13},{"nctId":"NCT04793958","phase":"PHASE3","title":"Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mirati Therapeutics Inc.","startDate":"2021-06-24","conditions":"Advanced Colorectal Cancer, Metastatic Colorectal Cancer","enrollment":461},{"nctId":"NCT02162563","phase":"PHASE3","title":"Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases","status":"COMPLETED","sponsor":"Dutch Colorectal Cancer Group","startDate":"2014-07","conditions":"Colorectal Cancer, Liver Metastases","enrollment":530},{"nctId":"NCT06767007","phase":"PHASE2","title":"SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal Cancer（SPARKLE）","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2025-01-06","conditions":"Unresectable Locally Recurrent Rectal Cancer","enrollment":31},{"nctId":"NCT06139211","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2024-01-03","conditions":"Advanced Solid Tumor","enrollment":186},{"nctId":"NCT05462613","phase":"PHASE2, PHASE3","title":"Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2023-05-09","conditions":"Metastatic Colorectal Cancer","enrollment":446},{"nctId":"NCT05534087","phase":"PHASE3","title":"Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2022-12-15","conditions":"Colon Cancer","enrollment":236},{"nctId":"NCT03009058","phase":"PHASE1, PHASE2","title":"Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer","status":"TERMINATED","sponsor":"Immodulon Therapeutics Ltd","startDate":"2017-05-31","conditions":"Metastatic Cancer","enrollment":2},{"nctId":"NCT03374254","phase":"PHASE1","title":"Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-02-16","conditions":"Metastatic Colorectal Cancer","enrollment":116},{"nctId":"NCT04021277","phase":"PHASE1","title":"PS101-mediated ACT With Chemotherapy in Liver Metastases From Cancer of Gastrointestinal Origin","status":"TERMINATED","sponsor":"EXACT Therapeutics AS","startDate":"2019-09-17","conditions":"Solid Tumor, Colorectal Cancer","enrollment":11},{"nctId":"NCT04535401","phase":"PHASE1","title":"Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-13","conditions":"Advanced Colorectal Carcinoma, Advanced Digestive System Carcinoma, Advanced Gastric Carcinoma","enrollment":10},{"nctId":"NCT04258969","phase":"NA","title":"Pedaling at a Low-Moderate Intensity During Chemotherapy Administration","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"2020-01-11","conditions":"Colorectal Cancer, Exercise, Aerobic, Chemotherapy","enrollment":""},{"nctId":"NCT05628038","phase":"PHASE2","title":"The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-11-30","conditions":"Recurrent Rectal Cancer","enrollment":93},{"nctId":"NCT05084859","phase":"PHASE1","title":"A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Biosplice Therapeutics, Inc.","startDate":"2021-11-03","conditions":"Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer, Colorectal Cancer","enrollment":30},{"nctId":"NCT04926545","phase":"NA","title":"XCHT for Irinotecan-Induced Gut Toxicities (Run-in Study)","status":"COMPLETED","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2021-07-16","conditions":"Malignant Tumor, Diarrhea","enrollment":24},{"nctId":"NCT06509126","phase":"PHASE3","title":"Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2024-06-12","conditions":"Colorectal Cancer Stage IV","enrollment":500},{"nctId":"NCT02352337","phase":"PHASE2","title":"First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2015-01-12","conditions":"Metastatic Pancreatic Cancer","enrollment":276},{"nctId":"NCT02827201","phase":"PHASE2","title":"FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2015-11","conditions":"Metastatic Pancreatic Cancer","enrollment":127},{"nctId":"NCT03250832","phase":"PHASE1","title":"Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2017-08-08","conditions":"Neoplasms","enrollment":111},{"nctId":"NCT05522738","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2022-08-10","conditions":"Metastatic Colorectal Cancer","enrollment":46},{"nctId":"NCT02928224","phase":"PHASE3","title":"Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-10-13","conditions":"BRAF V600E-mutant Metastatic Colorectal Cancer","enrollment":702},{"nctId":"NCT05015621","phase":"PHASE3","title":"A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma","status":"UNKNOWN","sponsor":"Hutchison Medipharma Limited","startDate":"2021-09-18","conditions":"Advanced Neuroendocrine Carcinoma","enrollment":194},{"nctId":"NCT03485027","phase":"PHASE2","title":"Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Fudan University","startDate":"2018-01-24","conditions":"Metastatic Colorectal Cancer, Chemotherapy Effect","enrollment":43},{"nctId":"NCT02753127","phase":"PHASE3","title":"A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2016-06","conditions":"Colorectal Cancer","enrollment":1253},{"nctId":"NCT04299880","phase":"PHASE1","title":"Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2020-02-24","conditions":"Oncology","enrollment":7},{"nctId":"NCT01133990","phase":"PHASE1, PHASE2","title":"FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Eisai Inc.","startDate":"2010-03-04","conditions":"Colorectal Cancer","enrollment":5},{"nctId":"NCT04392479","phase":"PHASE3","title":"TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.","status":"UNKNOWN","sponsor":"Hôpital Franco-Britannique-Fondation Cognacq-Jay","startDate":"2020-09-02","conditions":"Cancer Colorectal, Metastasis","enrollment":202},{"nctId":"NCT05862051","phase":"NA","title":"RESOLUTE Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2021-12-14","conditions":"Colorectal Cancer, Oligometastatic Disease","enrollment":75},{"nctId":"NCT04259944","phase":"PHASE2","title":"Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial","status":"UNKNOWN","sponsor":"IFOM ETS - The AIRC Institute of Molecular Oncology","startDate":"2020-06-16","conditions":"Colon Cancer","enrollment":140},{"nctId":"NCT05555901","phase":"PHASE2","title":"The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2023-06-18","conditions":"Metastatic Colorectal Cancer","enrollment":116},{"nctId":"NCT01726582","phase":"PHASE2","title":"Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery (\"Personalized Medicine\")","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2011-11","conditions":"Pancreatic Adenocarcinoma","enrollment":229},{"nctId":"NCT05842525","phase":"PHASE2","title":"Fruquintinib Plus FOLFIRI in RAS-mutated Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Hunan Cancer Hospital","startDate":"2023-10-01","conditions":"Colorectal Cancer","enrollment":42},{"nctId":"NCT01347645","phase":"PHASE1, PHASE2","title":"Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer","status":"TERMINATED","sponsor":"Eisai Inc.","startDate":"2011-09-30","conditions":"Colon Cancer, Rectal Cancer","enrollment":82},{"nctId":"NCT03253133","phase":"PHASE1","title":"Assessing Safety of NIPOX in Peritoneal Carcinomatosis of CRC","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2016-05-10","conditions":"Colorectal Cancer","enrollment":19},{"nctId":"NCT05742425","phase":"PHASE2","title":"Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-03","conditions":"Unresectable Colon Cancer Peritoneal Metastases, PMMR/Ras/BRAF Wild-type","enrollment":30},{"nctId":"NCT05684211","phase":"PHASE2","title":"A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer","status":"UNKNOWN","sponsor":"Shanghai Celfuture Biotech Co., Ltd.","startDate":"2023-01","conditions":"Colorectal Cancer","enrollment":84},{"nctId":"NCT05634590","phase":"PHASE2","title":"The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-12","conditions":"Metastatic Colorectal Cancer","enrollment":68},{"nctId":"NCT03665441","phase":"PHASE3","title":"Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC","status":"COMPLETED","sponsor":"ERYtech Pharma","startDate":"2018-09-15","conditions":"Pancreatic Adenocarcinoma","enrollment":512},{"nctId":"NCT00339183","phase":"PHASE3","title":"Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-06-30","conditions":"Metastatic Colorectal Cancer","enrollment":1186},{"nctId":"NCT04389086","phase":"PHASE3","title":"Induction Chemotherapy for Locally Recurrent Rectal Cancer","status":"RECRUITING","sponsor":"Catharina Ziekenhuis Eindhoven","startDate":"2020-11-13","conditions":"Recurrent Rectal Cancer","enrollment":364},{"nctId":"NCT02833753","phase":"PHASE1","title":"Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI","status":"COMPLETED","sponsor":"University of Massachusetts, Worcester","startDate":"2016-07","conditions":"Colorectal Cancer, Appendix Cancer, Peritoneal Carcinomatosis","enrollment":14},{"nctId":"NCT05316818","phase":"PHASE2","title":"Triplet (FOLFOXIRI) vs. Doublet (FOLFOX or FOLFIRI) Regimen as a 1st Line Treatment in Metastatic Colorectal Carcinoma","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2018-01-16","conditions":"Metastatic Colorectal Cancer","enrollment":64},{"nctId":"NCT03331640","phase":"PHASE2","title":"A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy","status":"TERMINATED","sponsor":"AIO-Studien-gGmbH","startDate":"2018-01-02","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":67},{"nctId":"NCT03311750","phase":"PHASE2","title":"Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer","status":"TERMINATED","sponsor":"Hellenic Cooperative Oncology Group","startDate":"2018-03-26","conditions":"Advanced Colorectal Cancer","enrollment":23},{"nctId":"NCT04270929","phase":"PHASE1","title":"Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma","status":"WITHDRAWN","sponsor":"Roger Williams Medical Center","startDate":"2019-12-23","conditions":"Pancreatic Adenocarcinoma","enrollment":""},{"nctId":"NCT04831528","phase":"","title":"Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical Study","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2021-04-10","conditions":"Metastatic Colorectal Cancer","enrollment":100},{"nctId":"NCT00066274","phase":"PHASE2","title":"Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2002-07-23","conditions":"Colorectal Cancer","enrollment":""},{"nctId":"NCT03031444","phase":"PHASE2, PHASE3","title":"Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis","status":"COMPLETED","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2016-01","conditions":"Colorectal Cancer Stage IV, Metastasis","enrollment":135},{"nctId":"NCT01394939","phase":"PHASE1, PHASE2","title":"Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma","status":"COMPLETED","sponsor":"Jennerex Biotherapeutics","startDate":"2012-01","conditions":"Colorectal Carcinoma, CRC","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"FOLFIRI.3","genericName":"FOLFIRI.3","companyName":"Federation Francophone de Cancerologie Digestive","companyId":"federation-francophone-de-cancerologie-digestive","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FOLFIRI is a chemotherapy regimen that combines 5-fluorouracil, leucovorin, irinotecan, and folinic acid to target rapidly dividing cancer cells. Used for Metastatic colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}